Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of methylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Methylphenidate has moderate liability among addictive drugs, with addiction and psychological dependence occurring primarily when used at high doses or in non-medical contexts. At therapeutic doses, it does not sufficiently activate the reward system to cause addiction; however, its dopamine reuptake inhibition can induce euphoria at higher doses, contributing to abuse potential.
Physical dependence and withdrawal are mainly reported with high-dose or non-medical use and are uncommon at therapeutic doses. Withdrawal symptoms following abrupt discontinuation may include lethargy, apathy, depression, and paranoia, but these are not life-threatening.
Methylphenidate overdose is rarely fatal with appropriate care. Severe overdose may cause hyperpyrexia, sympathomimetic toxidrome, convulsions, rhabdomyolysis, coma, and circulatory collapse.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 190 mg/kg |
Acute cardiovascular effects including elevated heart rate, blood pressure changes, and palpitations occur during use; these are typically mild at therapeutic doses. FDA studies found no association between medical use and serious cardiovascular events such as sudden death, heart attack, or stroke. Higher doses and overdose may cause cardiac arrhythmias.
Liver toxicity from methylphenidate is extremely rare; limited evidence suggests the risk may increase when combined with β-adrenergic agonists.
Rhabdomyolysis has been reported primarily in severe overdose situations or with large doses that induce hyperthermia and excessive muscular activity.
Intravenous injection of crushed tablet preparations can cause severe toxic reactions including abscess formation, tissue necrosis, and pulmonary or cerebral embolism due to insoluble binders and fillers.
Long-term treatment in children has been associated with mild reductions in height, estimated at approximately 1 cm or less per year during the first three years, with a total decrease of about 3 cm over 10 years of continuous treatment.
Methylphenidate can worsen psychosis in people who are already psychotic; in very rare cases, it has been associated with the emergence of new psychotic symptoms. Visual hallucinations are very rarely reported. Overdose may trigger hallucinations and delirium. Should be used with extreme caution in people with bipolar disorder due to potential induction of mania or hypomania.
Seizures and convulsions are associated with abusive use, higher doses, and severe overdose rather than typical therapeutic use. Convulsions in overdose may be followed by coma.
Methylphenidate was first synthesized in 1944 by Swiss chemist Leandro Panizzon while working for the pharmaceutical company CIBA (now Novartis). Panizzon named the compound after his wife Marguerite, nicknamed "Rita," who became the first person to take the substance. Rita used methylphenidate to
Widely available as a prescription medication across EU member states. Notably used more frequently in the EU than amphetamine-based alternatives like Adderall for ADHD treatment.
Available as a prescription medication with a blackbox warning indicating high potential for abuse and dependence. Multiple brand name formulations (including Adhansia XR, Metadate ER, Methylin) and generic products are marketed for medical use.
Available as a prescription medication, commonly prescribed for ADHD and narcolepsy. Marketed under various trade names including Rubifen.
11 sources cited
